- Home
- GLUE vs LINC Comparison
GLUE vs LINC Comparison
Compare GLUE & LINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | LINC |
|---|---|---|
| Founded | 2019 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GLUE | LINC |
|---|---|---|
| Price | $16.60 | $47.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $32.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 737.5K | 507.6K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.14 |
| Revenue | $123,672,000.00 | ★ $261,853,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $2.45 | $9.02 |
| P/E Ratio | ★ $72.42 | $342.79 |
| Revenue Growth | ★ 63.54 | 32.98 |
| 52 Week Low | $4.12 | $17.29 |
| 52 Week High | $25.77 | $53.50 |
Technical Indicators
Market Signals| Indicator | GLUE | LINC |
|---|---|---|
| Relative Strength Index (RSI) | 36.13 | 52.52 |
| Support Level | $14.43 | $45.85 |
| Resistance Level | $18.66 | $50.06 |
| Average True Range (ATR) | 1.07 | 2.05 |
| MACD | -0.30 | -0.30 |
| Stochastic Oscillator | 13.18 | 31.85 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.